Literature DB >> 11922938

GPI-anchoring of GM-CSF results in active membrane-bound and partially shed cytokine.

Neil J Poloso1, Shanmugam Nagarajan, Jose M Mejia-Oneta, Periasamy Selvaraj.   

Abstract

Granulocyte-macrophage colony-stimulating factor (GM-CSF) can induce the generation and activation of dendritic cells (DCs), the most potent of antigen presenting cells (APCs). Tumors secreting GM-CSF have been shown to induce strong anti-tumor immune responses. In this report, we have constructed a glycosylphosphatidyl-inositol (GPI) anchored form of GM-CSF (GPI-GM-CSF). This protein subsequently was found expressed on the cell membrane and sensitive to phosphatidyl-inositol-specific phospholipase C (PIPLC), confirming that it is GPI-anchored. However, GM-CSF was also found in the culture supernatant of cells expressing GPI-GM-CSF. Inhibition studies using brefeldin A and para-formaldehyde fixation revealed that GM-CSF found in the supernatant was not secreted, but due to shedding or proteolytic cleavage. Accumulation of GM-CSF in the media from isolated membranes was time and temperature-dependent. The released portion represented 10-15% of all membrane-bound GM-CSF after 72h under culture conditions. GPI-GM-CSF retained functional activity to induce bone marrow cell proliferation and administration of GPI-GM-CSF expressing membranes induced the generation of DCs in vivo. These results demonstrate that GPI-anchored GM-CSF retains all functional activity of native GM-CSF while gaining the ability to attach to cell membranes. The ability of GPI-GM-CSF to be expressed on membranes and be partially released, can possibly lead to formation of a cytokine gradient, while retaining ability to target associated membrane antigens to DCs. This novel form of GM-CSF may have wide range of clinical applicability.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11922938     DOI: 10.1016/s0161-5890(02)00005-6

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  13 in total

1.  Safety and antitumor effect of oncolytic and helper-dependent adenoviruses expressing interleukin-12 variants in a hamster pancreatic cancer model.

Authors:  J Poutou; M Bunuales; M Gonzalez-Aparicio; E Garcia-Aragoncillo; J I Quetglas; R Casado; C Bravo-Perez; P Alzuguren; R Hernandez-Alcoceba
Journal:  Gene Ther       Date:  2015-05-04       Impact factor: 5.250

2.  Influenza virus-like particles engineered by protein transfer with tumor-associated antigens induces protective antitumor immunity.

Authors:  Jaina M Patel; Vincent F Vartabedian; Min-Chul Kim; Sara He; Sang-Moo Kang; Periasamy Selvaraj
Journal:  Biotechnol Bioeng       Date:  2015-04-17       Impact factor: 4.530

3.  Plasma membrane vesicles decorated with glycolipid-anchored antigens and adjuvants via protein transfer as an antigen delivery platform for inhibition of tumor growth.

Authors:  Jaina M Patel; Vincent F Vartabedian; Erica N Bozeman; Brianne E Caoyonan; Sanjay Srivatsan; Christopher D Pack; Paulami Dey; Martin J D'Souza; Lily Yang; Periasamy Selvaraj
Journal:  Biomaterials       Date:  2015-09-28       Impact factor: 12.479

4.  Co-delivery of GPI-anchored CCL28 and influenza HA in chimeric virus-like particles induces cross-protective immunity against H3N2 viruses.

Authors:  Teena Mohan; Jongrok Kim; Zachary Berman; Shelly Wang; Richard W Compans; Bao-Zhong Wang
Journal:  J Control Release       Date:  2016-05-10       Impact factor: 9.776

5.  Cancer immunotherapy using a membrane-bound interleukin-12 with B7-1 transmembrane and cytoplasmic domains.

Authors:  Wen-Yu Pan; Chia-Hui Lo; Chun-Chi Chen; Ping-Yi Wu; Steve R Roffler; Song-Kun Shyue; Mi-Hua Tao
Journal:  Mol Ther       Date:  2012-02-14       Impact factor: 11.454

6.  Incorporation of glycosylphosphatidylinositol-anchored granulocyte- macrophage colony-stimulating factor or CD40 ligand enhances immunogenicity of chimeric simian immunodeficiency virus-like particles.

Authors:  Ioanna Skountzou; Fu-Shi Quan; Sailaja Gangadhara; Ling Ye; Andrei Vzorov; Periasamy Selvaraj; Joshy Jacob; Richard W Compans; Sang-Moo Kang
Journal:  J Virol       Date:  2006-11-15       Impact factor: 5.103

Review 7.  Cancer vaccine development: protein transfer of membrane-anchored cytokines and immunostimulatory molecules.

Authors:  Ashley M Cimino; Purani Palaniswami; Andrew C Kim; Periasamy Selvaraj
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

8.  A novel method to incorporate bioactive cytokines as adjuvants on the surface of virus particles.

Authors:  Yufang Yang; David Leggat; Andrew Herbert; Paul C Roberts; Roys S Sundick
Journal:  J Interferon Cytokine Res       Date:  2009-01       Impact factor: 2.607

9.  Protein transfer-mediated surface engineering to adjuvantate virus-like nanoparticles for enhanced anti-viral immune responses.

Authors:  Jaina M Patel; Min-Chul Kim; Vincent F Vartabedian; Yu-Na Lee; Sara He; Jae-Min Song; Hyo-Jick Choi; Satoshi Yamanaka; Nikhil Amaram; Anna Lukacher; Carlo D Montemagno; Richard W Compans; Sang-Moo Kang; Periasamy Selvaraj
Journal:  Nanomedicine       Date:  2015-03-06       Impact factor: 5.307

10.  Cancer vaccine development: designing tumor cells for greater immunogenicity.

Authors:  Erica N Bozeman; Rangaiah Shashidharamurthy; Simon A Paulos; Ravi Palaniappan; Martin D'Souza; Periasamy Selvaraj
Journal:  Front Biosci (Landmark Ed)       Date:  2010-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.